The short version
7 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 79% in a year, to $0.8798 per unit — and generics that get this cheap tend to get abandoned rather than defended. A Class II recall hit this product in the past year (Rising Pharma Holding, Inc.). One of its named manufacturing plants, Eugia Pharma Specialities Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.